Literature DB >> 15992457

Patient preferences in prostate cancer: a clinician's guide to understanding health utilities.

Karen M Kramer1, Charles L Bennett, A Simon Pickard, E Allison Lyons, Michael S Wolf, June M McKoy, Sara J Knight.   

Abstract

Prostate cancer treatments have positive and negative outcomes that must be taken into account when deciding how to proceed with a patient's care. One way to quickly determine a patient's preferences in this situation is to ascertain their health utilities for various health states. Health utilities are underutilized but powerful tools in aiding shared decision making between patients and physicians. This review is intended to inform physicians about the different techniques available, help the physician choose among them, and aid initial development of utilities for use in the clinic by way of the tables' references. A brief history, summary of applications and current directions of health utilities, and collection of references are provided to increase the reader's overall knowledge of health utilities and encourage their use in the clinic. Ultimately, the use and choice of one of these direct preference-based measures depends on the needs of the physician.

Entities:  

Mesh:

Year:  2005        PMID: 15992457     DOI: 10.3816/cgc.2005.n.007

Source DB:  PubMed          Journal:  Clin Prostate Cancer        ISSN: 1540-0352


  15 in total

1.  High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?

Authors:  B A Mahal; M-H Chen; C L Bennett; M W Kattan; O Sartor; K Stein; A V D'Amico; P L Nguyen
Journal:  Ann Oncol       Date:  2015-04-28       Impact factor: 32.976

Review 2.  Pharmacoeconomics of available treatment options for metastatic prostate cancer.

Authors:  Steven B Zeliadt; David F Penson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

4.  Personality predicts prostate cancer treatment decision-making difficulty and satisfaction.

Authors:  Heather Orom; Louis A Penner; Brady T West; Tracy M Downs; Walter Rayford; Willie Underwood
Journal:  Psychooncology       Date:  2009-03       Impact factor: 3.894

5.  Changes in health state utilities with changes in body mass in the Diabetes Prevention Program.

Authors:  Ronald T Ackermann; Sharon L Edelstein; K M Venkat Narayan; Ping Zhang; Michael M Engelgau; William H Herman; David G Marrero
Journal:  Obesity (Silver Spring)       Date:  2009-04-23       Impact factor: 5.002

6.  Controversies on individualized prostate cancer care: gaps in current practice.

Authors:  Steven Joniau; David Pfister; Alexandre de la Taille; Franco Gaboardi; Alan Thompson; Maria J Ribal
Journal:  Ther Adv Urol       Date:  2013-10

Review 7.  Factors that influence patient preferences for prostate cancer management options: A systematic review.

Authors:  Timothy N Showalter; Mark V Mishra; John Fp Bridges
Journal:  Patient Prefer Adherence       Date:  2015-07-02       Impact factor: 2.711

8.  Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.

Authors:  Salimah H Meghani; Christopher S Lee; Alexandra L Hanlon; Deborah W Bruner
Journal:  BMC Med Inform Decis Mak       Date:  2009-11-27       Impact factor: 2.796

9.  Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT.

Authors:  E Elif Ozkan; Alper Ozseven; Z Arda Kaymak Cerkesli
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09

10.  Response shift due to diagnosis and primary treatment of localized prostate cancer: a then-test and a vignette study.

Authors:  Ida J Korfage; Harry J de Koning; Marie-Louise Essink-Bot
Journal:  Qual Life Res       Date:  2007-10-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.